Bryla J, Niedzeweicka,A
Tuesdays announcement by the Institute for Clinical and Economic Review (ICER) that weight-loss drugs from Novo Nordisk and Eli Lilly are now cost-effective is an important victory for the two pharmaceutical companies, being that the assessment could pave the way for growth in US companies health insurance plans for their employees, according to a statement from Bank of America, whose analyst Tim Anderson follows Novo Nordisks US competitor, Eli Lilly.
The effect of omega-3 supplements on renal function indices in chronic kidney patients undergoing hemodialysis
A redox-triggered bispecific supramolecular nanomedicine based on peptide self-assembly for high-efficacy and low-toxicity cancer therapy
In contrast, the CNSs antioxidant architecture remains only partially understood, and its complexity is heightened by neuronal heterogeneity and limited regenerative capacity
Theoharides TC, Tsilioni I, Patel AB, Doyle R